1921
Volume 100, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Human infection with leads to obstruction of the common bile duct by adult worms and disease characterized by biliary colic, epigastric pain, and nausea. Recommended treatment is a single dose of triclabendazole (TCBZ) (10 mg/kg). Because in the 1990s the Bolivian Altiplano bordering Lake Titicaca was thought to have the highest prevalence of human fascioliasis worldwide, the Bolivian Ministry of Health instituted TCBZ mass drug administration (MDA). From 2008 to 2016 (excepting 2015), one dose of 250 mg was administered, usually in September/October, to each resident of highly endemic regions willing to participate. This is apparently the first reported use of MDA for . The proportion of persons in key regions receiving TCBZ MDA was 87% in 2016. In 2017, we resurveyed key regions, and found that the MDA program had been dramatically successful. Whereas prevalence was reported as 26.9% in Huacullani/Tiahuanaco and 12.6% in Batallas in 1999, there was 0.7% prevalence in Huacullani/Tiahuanaco and 1% in Batallas in 2017. However, lessons from schistosomiasis control efforts suggest that for sustained control of infection, MDA needs to be maintained and coupled with measures to control infection in the intermediary snail and in the animal hosts of .

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0060
2019-05-20
2020-10-01
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/6/tpmd190060.html?itemId=/content/journals/10.4269/ajtmh.19-0060&mimeType=html&fmt=ahah

References

  1. Centers for Disease Control and Prevention (CDC), 2018. Parasites—Fascioliasis (Fasciola Infection): Biology. Available at: http://www.cdc.gov/parasites/fasciola/biology.html. Accessed December 7, 2018.
    [Google Scholar]
  2. Centers for Disease Control and Prevention (CDC), 2018. Parasites—Fascioliasis (Fasciola Infection): Epidemiology and Risk Factors. Available at: http://www.cdc.gov/parasites/fasciola/epi.html. Accessed December 7, 2018.
    [Google Scholar]
  3. Ashrafi K, Bargues MD, O’Neill S, Mas-Coma S, 2014. Fascioliasis: a worldwide parasitic disease of importance in travel medicine. Trav Med Infect Dis 12: 636649.
    [Google Scholar]
  4. Mas-Coma S, 2005. Epidemiology of fascioliasis in human endemic areas. J Helminthol 79: 207216.
    [Google Scholar]
  5. World Health Organization (WHO), 2006. Report of the WHO Informal Meeting on Use of Triclabendazole in Fascioliasis Control. Available at: http://www.who.int/neglected_diseases/preventive_chemotherapy/WHO_CDS_NTD_PCT_2007.1.pdf. Accessed December 7, 2018.
    [Google Scholar]
  6. Esteban JG, Flores A, Angles R, Strauss W, Aguirre C, Mas-Coma S, 1997. A population-based coprological study of human fascioliasis in a hyperendemic area of the Bolivian Altiplano. Trop Med Int Health 2: 695699.
    [Google Scholar]
  7. Mas-Coma S, Anglés R, Esteban JG, Bargues MD, Buchon P, Franken M, Strauss W, 1999. The northern Bolivian Altiplano: a region highly endemic for human fascioliasis. Trop Med Int Health 4: 454467.
    [Google Scholar]
  8. 1991. Available at: http://microbeonline.com/kato-katz-technique-principle-procedure-results. Accessed December 7, 2018.
  9. Mas-Coma S, Funatsu IR, Bargues MD, 2001. Fasciola hepatica and lymnaeid snails occurring at very high altitude in South America. Parasitology 123 (Suppl): S115S127.
    [Google Scholar]
  10. Venturina VM, Alejandro MA, Baltazar CP, Abes NS, Mingala CN, 2015. Evidence of Fasciola spp. resistance to albendazole, triclabendazole and bromofenofos in water buffaloes (Bubalus bubalis). Ann Parasitol 61: 283289.
    [Google Scholar]
  11. Novobilský A, Amaya Solis N, Skarin M, Höglund J, 2016. Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test. Int J Parasitol Drugs Drug Resist 6: 141147.
    [Google Scholar]
  12. Dugernier T, Geubel A, Bigaignon G, Cesbron JY, Coche E, 1986. Human fascioliasis: cure by mebendazole? A case report. Gastroenterol Clin Biol 10: 513516.
    [Google Scholar]
  13. Cabada MM, Lopez M, Arque E, Clinton White A, 2014. Prevalence of soil-transmitted helminths after mass albendazole administration in an indigenous community of the Manu jungle in Peru. Pathog Glob Health 108: 200205.
    [Google Scholar]
  14. Lopez M, White AC, Cabada MM, 2012. Burden of Fasciola hepatica infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg 86: 481485.
    [Google Scholar]
  15. Cabada MM, Goodrich MR, Graham B, Villanueva-Meyer PG, Lopez M, Arque E, White AC, 2014. Fascioliasis and eosinophilia in the highlands of Cuzco, Peru and their association with water and socioeconomic factors. Am J Trop Med Hyg 91: 989993.
    [Google Scholar]
  16. Curtale F, Abd-el Wahab Hassanein Y, El Wakeel A, Barduagni P, Savioli L, 2003. The school health programme in Behera: an integrated helminth control programme at governorate level in Egypt. Acta Trop 86: 295307.
    [Google Scholar]
  17. Curtale F, Hassanein YA, Savioli L, 2005. Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt. Trans R Soc Trop Med Hyg 99: 599609.
    [Google Scholar]
  18. WHO, 2012. Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases. Available at: http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf. Accessed December 7, 2018.
    [Google Scholar]
  19. Abudho BO, Ndombi EM, Guya B, Carter JM, Riner DK, Kittur N, Karanja DMS, Secor WE, Colley DG, 2018. Impact of four years of annual mass drug administration on prevalence and intensity of schistosomiasis among primary and high school children in western Kenya: a repeated cross-sectional study. Am J Trop Med Hyg 98: 13971402.
    [Google Scholar]
  20. Kittur N, Binder S, Campbell CH, King CH, Kinung’hi S, Olsen A, Magnussen P, Colley DG, 2017. Defining persistent hotspots: areas that fail to decrease meaningfully in prevalence after multiple years of mass drug administration with praziquantel for control of schistosomiasis. Am J Trop Med Hyg 97: 18101817.
    [Google Scholar]
  21. Rujeni N, Morona D, Ruberanziza E, Mazigo HD, 2017. Schistosomiasis and soil-transmitted helminthiasis in Rwanda: an update on their epidemiology and control. Infect Dis Poverty 6: 8.
    [Google Scholar]
  22. Ross AG et al., 2015. Can mass drug administration lead to the sustainable control of schistosomiasis? J Infect Dis 211: 283289.
    [Google Scholar]
  23. Inobaya MT et al., 2018. Mass drug administration and the sustainable control of schistosomiasis: an evaluation of treatment compliance in the rural Philippines. Parasit Vectors 11: 441.
    [Google Scholar]
  24. Lelo AE et al., 2014. No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in Mwea, central Kenya, a heavy transmission area. PLoS Negl Trop Dis 8: e3221.
    [Google Scholar]
  25. Tchuem Tchuenté LA, Rollinson D, Stothard JR, Molyneux D, 2017. Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies. Infect Dis Poverty 6: 42.
    [Google Scholar]
  26. Villegas F et al., 2012. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS Negl Trop Dis 6: e1720.
    [Google Scholar]
  27. Maco V, Marcos L, Delgado J, Herrera J, Nestares J, Terashima A, Samalvides F, Gotuzzo E, 2015. Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children. Rev Soc Bras Med Trop 48: 445453.
    [Google Scholar]
  28. Kelley JM, Elliott TP, Beddoe T, Anderson G, Skuce P, Spithill TW, 2016. Current threat of triclabendazole resistance in Fasciola hepatica. Trends Parasitol 32: 458469.
    [Google Scholar]
  29. Cabada MM, Lopez M, Cruz M, Delgado JR, Hill V, White AC, 2016. Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series. PLoS Negl Trop Dis 10: e0004361.
    [Google Scholar]
  30. Webb CM, Cabada MM, 2018. Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection. Curr Opin Infect Dis 31: 409414.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0060
Loading
/content/journals/10.4269/ajtmh.19-0060
Loading

Data & Media loading...

  • Received : 21 Jan 2019
  • Accepted : 19 Feb 2019
  • Published online : 20 May 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error